About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary




Idarubicin

Beyond A CR - Postinduction Options
With A Compendium Of Articles On Critical Choices In Aml Today



Achieving A CR

SIGNIFICANTLY LESS RESISTANT DISEASE OCCURS WITH IDAMYCIN IN THE REGIMEN

  • Less resistant disease due to persistent blasts means greater responses
  • Greater responses lead to more postinduction options for patients


SIGNIFICANTLY FEWER PATIENTS HAVE HAD PERSISTENT BLASTS* ON THE IDAMYCIN ARM IN EACH STUDY

Bar Chart

Abbreviations: IDA, idarubicin; DNR, daunorubicin
*Of evaluable or assessable patients



SIGNIFICANTLY HIGHER CR RATES OCCUR WITH IDAMYCIN IN THE REGIMEN**

  • Consistently more CRs achieved after the first course of therapy
  • More durable therapy with consistently longer CRs Greater responses, more opportunity for postinduction options

**In two of three US studies.



CR RATES CONSISTENTLY HIGHER ON THE IDAMYCIN ARM IN EACH STUDY


CRs after
one course

CRs after
two courses


Berman1

Bar Chart Bar Chart

P=.005

Wiernick2 Bar Chart Bar Chart

P=.08

Vogler3

Bar Chart Bar Chart

P=.03

Abbreviations: IDA, idarubicin; DNR, daunorubicin



ACHIEVING A CR WITH MINIMAL RESISTANT DISEASE —
ESSENTIAL FOR POSTINDUCTION OPTIONS

Allogeneic Transplantation

  • Most common reasons that patients aged <= 40 years with an HLA match did NOT undergo BMT were primary refractory disease and short complete remission (< 3 mo).[4]

Autologous Transplantation

  • Purging autologous bone marrow using monoclonal antibodies and cytotoxic agents can help achieve long-term DFS in many AML patients.[5]

Immunotherapy

  • "IL-2 appears to represent a therapeutic option for AML patients with limited/minimal residual disease."[6]


ACHIEVING A CR AND BEYOND — IN AML

Significantly fewer patients with resistant disease
Significantly higher complete remission rates*
Significantly longer survival*
Superior therapeutic profile during induction*
And options for postinduction therapy

*In two of three US studies



Idarubicin

TIME IS OF THE ESSENCE

Please click here for full prescribing information.

References:

  1. Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991;77:1666-1674.
  2. Wiernik PH, Banks PLC, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992;79:313-319.
  3. Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study. J Clin Oncol. 1992;10:1103-1111.
  4. Berman E, Little C, Gee T, et al. Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. N Engl J Med. 1992;326:156-160.
  5. Selvaggi KJ, Wilson JW, Mills LE, et al. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow. Blood. 1994;83:1698-1705.
  6. Foa R. Does interleukin-2 have a role in the management of acute leukemia? J Clin Oncol. 1993;11:1817-1825.

Pharmacia & Upjohn

Top - Leukemia Library Index - Idamycin Index

About Medicine OnLine Medicine OnLine Home PageCancer LibrariesDoseCalc OnlineOncology News
Cancer ForumsMedline SearchCancer LinksGlossary